Label
Interaction expected – Do not coadminister
Color
Red
Red: Avoid combination
| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Rilpivirine Esomeprazole 123 | Red: Avoid combination | Do not coadminister: Reduced levels of rilpivirine | Decreased rilpivirine effects |
Contraindicated. Use alternative agents. |
|||
| Rilpivirine (IM) Dexamethasone | Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Decreased rilpivirine effects if dexamethasone is given as more than a single-dose treatment |
Use alternative agents if therapy requires more than a single dose treatment of dexamethasone. |
|||
| Rilpivirine (IM) Phenytoin | Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Decreased rilpivirine effects |
Use alternative agents |
|||
| Rilpivirine (IM) Phenobarbital | Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Decreased rilpivirine effects |
Use alternative agents |
|||
| Rilpivirine (IM) RFB | Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Decreased rilpivirine effects |
Use alternative agents |
|||
| Rilpivirine (IM) RIF | Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Decreased rilpivirine effects |
Use alternative agents |
|||
| Rilpivirine (IM) RPT | Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Decreased rilpivirine effects |
Use alternative agents |
|||
| Rilpivirine (IM) St. John's Wort (Hypericum perforatum) | Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Decreased rilpivirine effects |
Use alternative agents |
|||
| Rilpivirine (IM) Oxcarbazepine | Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Decreased rilpivirine effects |
Use alternative agents |
|||
| Rilpivirine (IM) CBZ | Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Decreased rilpivirine effects |
Use alternative agents |
|||
| Lenacapavir St. John's Wort | Red: Avoid combination | Do not coadminister: reduced levels of lenacapavir | Potential loss of antiviral efficacy |
Contraindicated. Use alternative agents. |
|||
| Lenacapavir Rifapentine | Red: Avoid combination | Do not coadminister: reduced levels of lenacapavir | Potential loss of antiviral efficacy |
Use alternative agents |
|||
| Lenacapavir Rifabutin | Red: Avoid combination | Do not coadminister: reduced levels of lenacapavir | Potential loss of antiviral efficacy |
Use alternative agents |
|||
| Lenacapavir Quinidine | Red: Avoid combination | Do not coadminister: potentially increased levels of quinidine | Potential increased risk of quinidine adverse effects |
Use alternative agents. |
|||
| Lenacapavir Primidone | Red: Avoid combination | Do not coadminister: reduced levels of lenacapavir | Potential loss of antiviral efficacy |
Use alternative agents. |
|||
| Lenacapavir Pimozide | Red: Avoid combination | Do not coadminister: potentially increased levels of pimozide | Potential increased risk of pimozide adverse effects |
Contraindicated. Use alternative agents |
|||
| Lenacapavir Phenytoin | Red: Avoid combination | Do not coadminister: reduced levels of lenacapavir | Potential loss of antiviral efficacy |
Contraindicated. Use alternative agents. |
|||
| Lenacapavir Phenobarbital | Red: Avoid combination | Do not coadminister: reduced levels of lenacapavir | Potential loss of antiviral efficacy |
Use alternative agents |
|||
| Lenacapavir Oxcarbazepine | Red: Avoid combination | Do not coadminister: reduced levels of lenacapavir | Potential loss of antiviral efficacy |
Use alternative agents |
|||
| Lenacapavir Nevirapine | Red: Avoid combination | Do not coadminister: reduced levels of lenacapavir | Potential loss of antiviral efficacy |
Use alternative agents |
|||
| Lenacapavir Methylergonovine | Red: Avoid combination | Do not coadminister: potentially increased levels of methylergonovine | Increased risk of methylergonovine adverse effects |
Use alternative agents |
|||
| Lenacapavir Lomitapide | Red: Avoid combination | Do not coadminister: potentially increased levels of lomitapide | Potential increased risk of lomitapide adverse effects |
Contraindicated. Use alternative agents |
|||
| Lenacapavir Lamborexant | Red: Avoid combination | Do not coadminister: potentially increased levels of lamborexant | Potential increased risk of excessive sedation |
Use alternative agents. |
|||
| Lenacapavir Ivabradine | Red: Avoid combination | Do not coadminister: potentially increased levels of ivabradine | Potential increased risk of ivabradine adverse effects |
Use alternative agents. |
|||
| Lenacapavir Flibanserin | Red: Avoid combination | Do not coadminster: potentially increased levels of flibanserin | Potential increased risk of GI adverse effects, insomnia, dry mouth, tachycardia |
Use alternative agents. |
|||
| Lenacapavir Etravirine | Red: Avoid combination | Do not coadminister: potentially reduced levels of lenacapavir | Potential loss of antiviral efficacy |
Use alternative agents. |
|||
| Lenacapavir Eslicarbazepine | Red: Avoid combination | Do not coadminister: reduced levels of lenacapavir | Potential loss of antiviral efficacy |
Use alternative agents. |
|||
| Lenacapavir Ergotamine | Red: Avoid combination | Do not coadminister: potentially increased levels of ergotamine | Increased risk of ergotamine adverse effects |
Use alternative agents |
|||
| Lenacapavir Efavirenz | Red: Avoid combination | Do not coadminister: decreased levels of lenacapavir | Potential for loss of lenacapavir efficacy |
AUC decreased 55%; Cmax decreased 36% |
600 mg daily (fasted) | Not reported |
Use alternative agents |
| Lenacapavir Disopyramide | Red: Avoid combination | Do not coadminister: potentially increased levels of disopyramide | Potential increased risk of disopyramide adverse effects |
Use alternative agents. |
|||
| Lenacapavir Dihydroergotamine | Red: Avoid combination | Do not coadminister: potentially increased levels of dihydroergotamine | Increased risk of dihydroergotamine adverse effects |
Use alternative agents |
|||
| Lenacapavir Cisapride | Red: Avoid combination | Do not coadminister: potentially increased levels of cisapride | Potential increased risk of cisapride adverse effects |
Contraindicated. Use alternative agents |
|||
| Lenacapavir Carbamazepine | Red: Avoid combination | Do not coadminister: reduced levels of lenacapavir | Potential loss of antiviral efficacy |
Contraindicated. Use alternative agents. |
|||
| Lenacapavir Atazanavir/ritonavir | Red: Avoid combination | Do not coadminister: potentially increased levels of lenacapavir | Potential increase in lenacapavir adverse effects |
Use alternative agents |
|||
| Lenacapavir Atazanavir/cobicistat | Red: Avoid combination | Do not coadminister: increased levels of atazanavir | Potential for increased atazanavir adverse effects (e.g. hyperbilirubinemia, gastrointestinal effects). |
AUC increased 321%; Cmax increased 560% |
300/150 mg daily (fed state) | Not reported |
Use alternative agents |
| Lenacapavir Amiodarone | Red: Avoid combination | Do not coadminister: potentially increased levels of amiodarone | Potential increased risk of amiodarone and lenacapavir adverse effects |
Use alternative agents. |
|||
| Lenacapavir Rifampin | Red: Avoid combination | Do not coadminister: decreased levels of lenacapavir | Potential decrease in antiretroviral efficacy |
AUC decreased 84%; Cmax decreased 55% |
600 mg daily (fasted) | Not reported |
Use alternative agents |
| Ritonavir Voriconazole 1087 | Red: Avoid combination | Do not coadminister: Reduced levels of voriconazole | Decreased voriconazole effects |
No significant change |
400 mg Q12H | Voriconazole AUC decreased 83%; Cmax decreased 68% |
Do not coadminister with ritonavir or other ritonavir-boosted protease inhibitors unless benefit outweighs risks. If coadministering consider therapeutic drug monitoring. |
| Ritonavir Voriconazole 1086 | Red: Avoid combination | Do not coadminister: Reduced levels of voriconazole | Decreased voriconazole effects |
No significant change |
400 mg Q12H | Voriconazole AUC decreased 39%; Cmax decreased 24% |
Do not coadminister with ritonavir or other ritonavir-boosted protease inhibitors unless benefit outweighs risks. If coadministering consider therapeutic drug monitoring. |
| Ritonavir RIF 1085 | Red: Avoid combination | Do not coadminister: Reduced levels of ritonavir | Decreased ritonavir effects |
Ritonavir AUC decreased 35%; Cmax decreased 25% |
300 mg or 600 mg x 10 days | Use alternative agents |
|
| Ritonavir Ethinyl estradiol / Norethindrone acetate 1084 | Red: Avoid combination | Do not coadminister: Reduced levels of ethinyl estradiol | Decreased oral contraceptive effectiveness |
50 mcg x 2 doses | Ethinyl estradiol Cmax decreased 32%; AUC decreased 41% |
Use alternative contraceptive method |
|
| Ritonavir St. John's Wort (Hypericum perforatum) 1083 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of ritonavir | Decreased ritonavir effects |
Not studied (may decrease ritonavir levels) |
Not studied |
Contraindicated. Use alternative agents. |
|
| Ritonavir Quinidine 1082 | Red: Avoid combination | Do not coadminister: Potential for increased levels of quinidine | Increased quinidine effects (eg, cardiac arrhythmias) |
Not studied |
Not studied (may increase quinidine levels) |
Use alternative agents |
|
| Ritonavir Propafenone 1081 | Red: Avoid combination | Do not coadminister: Potential for increased levels of propafenone | Increased propafenone effects (eg, cardiac arrhythmias) |
Not studied |
Not studied (may increase propafenone levels) |
Use alternative agents |
|
| Ritonavir Pimozide 1080 | Red: Avoid combination | Do not coadminister: Potential for increased levels of pimozide | Increased pimozide effects (eg, hypotension, cardiac arrhythmias) |
Not studied |
Not studied (may increase pimozide levels) |
Contraindicated. Use alternative agents. |
|
| Ritonavir Ergotamine 1079 | Red: Avoid combination | Do not coadminister: Potential for increased levels of ergotamine | Increased ergotamine effects (eg, ergotism) |
Not studied |
Not studied (may increase ergotamine levels) |
Contraindicated. Use alternative agents. |
|
| Ritonavir ATV/c 1078 | Red: Avoid combination | Do not coadminister: Potential for increased levels of atazanavir | Potential atazanavir-associated adverse effects (hyperbilirubinemia, GI upset, etc.) |
Not studied |
Not studied; Potential increased atazanavir levels) |
Do not coadminister ritonavir or ritonavir containing products with atazanavir / cobicistat |
|
| Ritonavir Amiodarone 1077 | Red: Avoid combination | Do not coadminister: Potential for increased levels of amiodarone | Increased amiodarone effects (eg, cardiac arrhythmias) |
Not studied |
Not studied (may increase amiodarone levels) |
Do not coadminister |
|
| Ritonavir Alfuzosin 1076 | Red: Avoid combination | Do not coadminister: Potential for increased levels of alfuzosin | Not studied |
Not studied (may increase alfuzosin levels) |
Use alternative agents |
||
| Ritonavir Tinidazole 1075 | Red: Avoid combination | Do not coadminister: potential toxicity | Disulfiram-like reaction (eg, headache, hypotension, flushing, vomiting) |
Not studied |
Not studied |
Do not coadminister with ritonavir solution |
|
| Ritonavir Metronidazole 1074 | Red: Avoid combination | Do not coadminister: potential toxicity | Disulfiram-like reaction (eg, headache, hypotension, flushing, vomiting) |
Not studied |
Not studied |
Do not coadminister with ritonavir solution |
|
| Ritonavir Disulfiram 1073 | Red: Avoid combination | Do not coadminister: potential toxicity | Disulfiram reaction (eg, headache, hypotension, flushing, vomiting) |
Not studied |
Oral solution contains alcohol |
Do not coadminister with ritonavir solution |
|
| Ritonavir Triazolam 1072 | Red: Avoid combination | Do not coadminister: Increased levels of triazolam | Increased triazolam effects (eg, increased confusion, sedation, respiratory depression) |
0.125 mg x 1 dose | Triazolam AUC increased 1939%; half-life: increased 1267%; Cmax increased 87% |
Use alternative agents |
|
| Ritonavir Fluticasone 1071 | Red: Avoid combination | Do not coadminister: Increased levels of fluticasone | Increased fluticasone effects (eg, Cushing's syndrome, adrenal suppression) |
200 mcg once daily x 7 d | Fluticasone Cmax increased 2572%; AUC increased 36697% |
Avoid combination and use alternative agents |
|
| Ritonavir Fluticasone 1070 | Red: Avoid combination | Do not coadminister: Increased levels of fluticasone | Decreased plasma cortisol concentrations (eg, Cushing's syndrome, adrenal suppression) |
Fluticasone AUC increased 350-fold; Cmax increased 25-fold |
Avoid combination and use alternative agents |
||
| Darunavir Ethinyl estradiol / Norethindrone acetate 959 | Red: Avoid combination | Do not coadminister: Reduced levels of ethinyl estradiol and norethindrone | Potential decreased ethinyl estradiol and norethindrone effects (e.g. contraceptive failure) |
No significant change |
35 mcg / 1.0 mg once daily | Ethinyl estradiol: Cmax decrease 32%, AUC decrease 44%, Cmin decrease 62%; Norethindrone: Cmax decrease 10%, AUC decrease 14%, Cmin decrease 30% |
Use alternative agents. If coadministering, back-up contraceptive methods are recommended. |
| Darunavir Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 958 | Red: Avoid combination | Do not coadminister: Reduced levels of darunavir | Potential decreased anti-HCV and anti-HIV efficacy |
Darunavir Cmax decreased 8%; AUC decreased 24%; Cmin decreased 48% |
250 mg BID + 25 / 150 / 100 mg once daily | Dasabuvir Cmax increase 10%, AUC decrease 6%, Cmin increase 10%; Ombitasvir Cmax and AUC decrease 14%, Cmin decrease 13%; Paritaprevir Cmin increase 54%, AUC increase 29%, Cmin increase 30% |
Use alternative agents |
| Darunavir Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 957 | Red: Avoid combination | Do not coadminister: Reduced levels of darunavir | Potential decreased anti-HCV and anti-HIV efficacy |
Cmax decrease 21%, AUC increase 34%, Cmin decrease 46% |
250 mg BID + 25 / 150 / 100 mg once daily | Dasabuvir Cmax decrease 25%, AUC decrease 28%, Cmin decrease 35%; Ombitasvir Cmax, AUC, and Cmin decrease 13%; Paritaprevir Cmax decrease 30%, AUC decrease 19%, Cmin increase 59% |
Use alternative agents |
| Darunavir Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 956 | Red: Avoid combination | Do not coadminister: Reduced levels of darunavir | Potential decreased anti-HCV and anti-HIV efficacy |
Cmax decrease 13%, AUC decrease 20%, Cmin decrease 43% |
250 mg BID + 25 / 150 / 100 mg once daily | Dasabuvir Cmax decrease 16%, AUC decrease 27%; Cmin decrease 46%; Ombitasvir Cmax decrease 24%, AUC and Cmin decrease 27%; Paritaprevir Cmax decrease 30%, AUC decrease 41%, Cmin decrease 17% |
Use alternative agents |
| Darunavir Phenytoin 955 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of darunavir | Potential loss of antiviral efficacy |
Contraindicated. Use alternative agents. |
|||
| Darunavir Phenobarbital 954 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of darunavir | Potential loss of antiviral efficacy |
Contraindicated. Use alternative agents. |
|||
| Darunavir St. John's Wort (Hypericum perforatum) 953 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of darunavir | Potential loss of antiviral efficacy |
Contraindicated. Use alternative agents. |
|||
| Darunavir CBZ 952 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of darunavir | Potential loss of antiviral efficacy |
Contraindicated. Use alternative agents. |
|||
| Darunavir RIF 951 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of darunavir | Potential loss of antiviral efficacy |
Contraindicated. Use alternative agents. |
|||
| Darunavir Suvorexant 950 | Red: Avoid combination | Do not coadminister: Potential for increased suvorexant levels | Potential for increased risk of suvorexant adverse effects |
Use alternative agents |
|||
| Darunavir Perphenazine 949 | Red: Avoid combination | Do not coadminister: Potential for increased perphenazine levels | Potential for increased risk of perphenazine adverse effects |
Contraindicated. Use alternative agents. |
|||
| Darunavir Naloxegol 948 | Red: Avoid combination | Do not coadminister: Potential for increased naloxegol levels | Potential for increased risk of precipitating opioid withdrawal |
Contraindicated. Use alternative agents. |
|||
| Darunavir Mexiletine 947 | Red: Avoid combination | Do not coadminister: Potential for increased mexiletine levels | Potential for increased risk of mexiletine adverse effects |
Use alternative agents |
|||
| Darunavir Lurasidone 946 | Red: Avoid combination | Do not coadminister: Potential for increased lurasidone levels | Potential for increased risk of lurasidone adverse effects |
Contraindicated. Use alternative agents. |
|||
| Darunavir Triazolam 945 | Red: Avoid combination | Do not coadminister: Potential for increased levels of triazolam | Potential for increased risk of triazolam adverse effects (e.g. increased sedation, confusion, respiratory depression) |
Contraindicated. Use alternative agents. |
|||
| Darunavir Terfenadine 944 | Red: Avoid combination | Do not coadminister: Potential for increased levels of terfendaine | Potential for increased risk of terfenadine adverse effects (e.g. cardiac arrhythmias) |
Use alternative agents |
|||
| Darunavir Simvastatin 943 | Red: Avoid combination | Do not coadminister: Potential for increased levels of simvastatin | Increased risk of simvastatin adverse effects (e.g. myopathy, rhabdomyolysis) |
Not studied |
Not studied (may increase simvastatin levels) |
Contraindicated. Use alternative agents. |
|
| Darunavir Silodosin 942 | Red: Avoid combination | Do not coadminister: Potential for increased levels of silodosin | Potential for increased risk of silodosin adverse effects |
Contraindicated. Use alternative agents. |
|||
| Darunavir Ranolazine 941 | Red: Avoid combination | Do not coadminister: Potential for increased levels of ranolazine and darunavir | Potential for increased risk of ranolazine adverse effects (e.g. prolonged QT, cardiac arrythmias) |
Use alternative agents |
|||
| Darunavir Pimozide 940 | Red: Avoid combination | Do not coadminister: Potential for increased levels of pimozide | Potential for increased risk of pimozide adverse effects (e.g. hypotension, cardiac arrhythmias) |
Contraindicated. Use alternative agents. |
|||
| Darunavir HMG-CoA Reductase Inhibitors 939 | Red: Avoid combination | Do not coadminister: Potential for increased levels of lovastatin | Increased risk of lovastatin adverse effects (e.g. myopathy, rhabdomyolysis) |
Not studied |
Not studied (may increase lovastatin levels) |
Contraindicated. Use alternative agents. |
|
| Darunavir Lomitapide 938 | Red: Avoid combination | Do not coadminister: Potential for increased levels of lomitapide | Potential for increased risk of lomitapide adverse effects |
Not studied |
Not studied |
Contraindicated. Use alternative agents. |
|
| Darunavir Ergotamine 937 | Red: Avoid combination | Do not coadminister: Potential for increased levels of ergotamine | Potential for increased risk of ergotamine adverse effects (e.g. peripheral vasospasm, ischemia) |
Contraindicated. Use alternative agents. |
|||
| Darunavir Dofetilide 936 | Red: Avoid combination | Do not coadminister: Potential for increased levels of dofetilide | Potential for increased risk of dofetilide adverse effects |
Use alternative agents |
|||
| Darunavir Disopyramide 935 | Red: Avoid combination | Do not coadminister: Potential for increased levels of disopyramide | Potential for increased risk of disopyramide adverse effects |
Use alternative agents |
|||
| Darunavir Alfuzosin 934 | Red: Avoid combination | Do not coadminister: Potential for increased levels of alfuzosin | Potential for increased risk of alfuzosin adverse effects (e.g. hypotension) |
Contraindicated. Use alternative agents. |
|||
| Darunavir Ivabradine 933 | Red: Avoid combination | Do not coadminister: Potential for increased ivabradine levels | Potential for increased risk of ivabradine adverse effects (e.g. prolonged QT, cardiac arrythmias) |
Use alternative agents |
|||
| Darunavir Irinotecan 932 | Red: Avoid combination | Do not coadminister: Potential for increased irinotecan levels | Potential for increased risk of irinotecan adverse effects |
Discontinue DRV / c at least 1wk prior to starting irinotecan. Do not coadminister unless there are no therapeutic alternatives |
|||
| Darunavir G/P 931 | Red: Avoid combination | Do not coadminister: Potential for increased glecaprevir / pibrentasvir levels | Potential for increased glecaprevir / pibrentasvir adverse effects |
Use alternative agents |
|||
| Darunavir Flibanserin 930 | Red: Avoid combination | Do not coadminister: Potential for increased flibanserin levels | Potential for increased risk of flibanserin adverse effects |
Contraindicated. Use alternative agents. |
|||
| Darunavir Everolimus 929 | Red: Avoid combination | Do not coadminister: Potential for increased everolimus levels | Potential for increased risk of everolimus adverse effects |
Not studied |
Not studied (may increase everolimus levels) |
Use alternative agents |
|
| Darunavir Eplerenone 928 | Red: Avoid combination | Do not coadminister: Potential for increased eplerenone levels | Potential for increased risk of eplerenone adverse effects |
Contraindicated. Use alternative agents. |
|||
| Darunavir Dronedarone 927 | Red: Avoid combination | Do not coadminister: Potential for increased dronedarone levels | Potential for increased risk of dronedarone adverse effects |
Use alternative agents |
|||
| Darunavir Dihydroergotamine 926 | Red: Avoid combination | Do not coadminister: Potential for increased dihydroergotamine levels | Potential for increased risk of dihydroergotamine adverse effects (e.g. peripheral vasospasm, ischemia) |
Contraindicated. Use alternative agents. |
|||
| Darunavir Bedaquiline 925 | Red: Avoid combination | Do not coadminister: Potential for increased bedaquiline levels | Potential for increased risk of bedaquiline adverse effects |
Avoid combination and use alternative agents. If coadministering, monitor liver function and QTc interval |
|||
| Darunavir Avanafil 924 | Red: Avoid combination | Do not coadminister: Potential for increased avanafil levels | Potential for increased risk of avanafil adverse effects |
Use alternative agents |
|||
| Darunavir RPT 923 | Red: Avoid combination | Do not coadminister: Potential for decreased darunavir levels | Potential loss of antiviral efficacy |
Use alternative agents |
|||
| Darunavir Clopidogrel 922 | Red: Avoid combination | Do not coadminister: Potential for decreased clopidogrel levels | Potential for increased bleeding risk |
Use alternative agents |
|||
| Darunavir Propafenone 921 | Red: Avoid combination | Do not coadminister: Increased levels of propafenone | Potential for increased risk of propafenone adverse effects |
Use alternative agents |
|||
| Darunavir EBR/GZR 920 | Red: Avoid combination | Do not coadminister: Increased levels of grazoprevir | Potential for increased risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1 / 3 inhibition |
No significant change |
50 / 100 mg once daily | Elbasvir AUC increase 66%; Grazoprevir AUC increase 7.5 fold |
Contraindicated. Use alternative agents. |
| Darunavir Flecainide 919 | Red: Avoid combination | Do not coadminister: Increased levels of flecainide | Potential for increased risk of flecainide adverse effects |
Use alternative agents |
|||
| Atazanavir ETR 841 | Red: Avoid combination | Do not coadminister: Reduced levels of atazanavir and increased levels of etravirine | Potential increased etravirine effects, decreased atazanavir effects |
Atazanavir AUC decreased 17%, Cmin decreased 47% |
Etravirine AUC increased 50%, Cmax increased 47%, Cmin increased 58% |
Use alternative agents |
|
| Atazanavir EVG/c 840 | Red: Avoid combination | Do not coadminister: Reduced levels of atazanavir | Potential loss of antiretroviral efficacy |
Atazanavir Cmax decreased 24%, Cmin decreased 20% |
Elvitegravir 85 mg daily with cobicistat 150 mg daily | Elvitegravir AUC increased 17%, Cmax decreased 16%, Cmin increased 83% |
Use alternative agents |
| Atazanavir RIF 839 | Red: Avoid combination | Do not coadminister: Reduced levels of atazanavir | Potential loss of antiretroviral efficacy |
Atazanavir AUC no significant change, Cmax decreased 18%, Cmin decreased 40%(compared to atazanavir 400 mg daily) |
600 mg daily x 10 d | Not reported |
Contraindicated. Use alternative agents. |
| Atazanavir RIF 838 | Red: Avoid combination | Do not coadminister: Reduced levels of atazanavir | Potential loss of antiretroviral efficacy |
Atazanavir AUC decreased 72%, Cmax decreased 53%, Cmin decreased 98% |
600 mg daily x 10 d | Not reported |
Contraindicated. Use alternative agents. |
